期刊文献+

反相HPLC法测定大鼠血浆中17-烯丙胺基-17-脱甲基格尔德霉素及其代谢产物17-氨基-17-脱甲基格尔德霉素 被引量:1

RP-HPLC Measurement of 17-Allylamino-17-Demethoxygeldanamycin and Its Active Metabolite 7-Amino-17-Demethoxygeldanamycin in Rat Plasma
下载PDF
导出
摘要 目的:建立大鼠血浆中17-烯丙胺基-17-脱甲基格尔德雷素(17AAG)和17-氨基-17-脱甲基格尔德雷素(17AG)的反相高效液相色谱分析方法,用于17AAG 及其主要代谢产物17AG 的临床前药代动力学研究。方法:以α-萘酚为内标,用乙酸乙酯将17AAG 和17AG 从大鼠血浆中萃取分离吹干后,流动相复溶,HPLC 分析。色谱柱为日产迪玛 Inertsil-ODS 3色谱柱(250 mm×4.6 mm,5 μm),流动相为乙腈-25 mmol·L^(-1)磷酸盐缓冲液(含三乙胺10 mmol·L^(-1))(55:45,pH=3.0),流速1 mL·min^(-1),紫外检测波长313 nm。结果:17AAG、17AG 及内标α-萘酚与内源性干扰分离良好,17AAG 和17AG 在10.0-16000.0μg·L^(-1)浓度范围内呈良好线性关系,相关系数分别为0.9992和0.9987,平均萃取回收率均大于80%,内标回收率为85%。2种组分的最低定量限为10μg·L^(-1)。17AAG 日内 RSD 为2.9%~11.3%,日间 RSD 为6.5%~18.5%;17AG 日内RSD 为3.0%~3.8%,日间 RSD 为5.9%~16.4%。大鼠舌下静脉推注17AAG 15 mg·kg^(-1)后,其主要药动学参数为:CL=21.14 mL·min^(-1)·kg^(-1),AUC=206.5μg·min·mL^(-1),t_(1/2α)=24.82 min,t_(1/2β)=116.20 min,V\-c=1046.3 mL·kg^(-1)。结论:本法可满足17AAG 临床前药代动力学研究的要求。 Objective: To establish a sensitive RP- HPLC method for determining the concentration of 17 -allyl-amino - 17 - demethoxygeldanamycin (17AAG) and 17 - amino - 17 - demethoxygeldanamycin (17AG) in rat plasma. Methods: The plasma samples were extracted with ethyl acetate. The separation was performed on inertsil - ODS 3 column (4. 6 mm × 250 mm ,5 μm)and detected at UV wavelength of 313 nm. A mobile phase of 45 % (v/ v) 25 mmol · L^-1 sodium phosphate (pH 3.00)with 10 mmol · L^-1 triethylamine and 55% acetonitrile was run at a flow rate of 1 mL · min^ -1, α - Naphthoflavone as internal standard. Results: The linear ranges of 17AAG and 17AG were each 10. 0 ~ 16000. 0 μg · L^-1. The correlation coefficients of 17AAG and 17AG were 0. 9992 and 0. 9987. The lower limit of quantification was 10 μg · L^-1. The intra -day RSD were both less than 12% ;the inter -day RSD were both less than 19% and the average recoveries of 17AAG and 17AG were more than 80%. After single dose of 15 mg · kg^-1 in rat, the main pharmacokinetic parameters were estimated to be as follows:CL were 21.14 mL · min^-1 · kg^-1 ;AUC were 206. 5 μg · min ·mL ^-1, t1/2α=24.82min,t1/2β=116.20min,Vc=1046.3mL·kg^-1 , respectively. Conclusion: The established method is accurate and sensitive,It can be applied in the study of preclinical pharmacokinetics.
出处 《药物分析杂志》 CAS CSCD 北大核心 2005年第10期1161-1164,共4页 Chinese Journal of Pharmaceutical Analysis
基金 国家自然科学基金项目(30371669) 国家重大科技专项(863)资助项目(2003AA2Z347B)
  • 相关文献

参考文献4

  • 1Whitesell L, Mimnaugh EG, De Costa B ,et al. Inhibition of heat shock protein HSP90 - pp60v - src heteroprotein complex formation by benzoquinone ansamycins:essential role for stress proteins in oncogenic transformation. Proc Natl A cad Sci USA, 1994,91 ( 18 ) :8324.
  • 2Egorin MJ, Zuhowski EG, Rosen DM, et al. Plasma pharmacokinetics and tissue distribution of 17 - (allylamino) - 17 - demethoxygeldanamycin( NSC 330507 )in CK2F1 mice. Cancer Chemother Pharmacol,2001 47(4) :291.
  • 3Agnew E B, Wilson R H, Grem J L, et al. Measurement of the novel antitumor agent 17 - (allylamino) - 17 - demethoxygeldanamyein in human plasma by high - performance liquid chromatography. J Chromatogr B ,2001,237:243.
  • 4Shah V P, Midha K K, Dighe S, et al. Analytical methods validation :bioavailability, bioequivalence and pharmacokinetic studies. Pharm Res,1992,9( 4 ) :588.

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部